Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

DarioHealth Contracts with National Health Plan to Offer Behavioral Health Services to Millions of Members
October 15, 2021 (Investorideas.com Newswire) DarioHealth Corp. shares traded 17% higher after the company reported it entered into an agreement with an unnamed national healthcare provider to make its behavioral health products available to millions of the plan's members.

Pacira Bids to Acquire Flexion to Expand Leadership Position in Non-Opioid Pain Management
October 12, 2021 (Investorideas.com Newswire) Flexion Therapeutics Inc. shares traded 60% higher after the company reported it entered into a definitive agreement to be acquired by Pacira BioSciences Inc.

ChemoCentryx Shares Double After FDA Approves TAVNEOS for Treatment of ANCA-Associated Vasculitis
October 11, 2021 (Investorideas.com Newswire) Shares of ChemoCentryx Inc. traded 96% higher after the company reported the U.S. FDA approved its orally administered TAVNEOS (avacopan) for use in treatment of ANCA-associated vasculitis

Reliq's Telemedicine Platform Helps Free Up Hospital Space for COVID-19 Delta Patients
October 7, 2021 (Investorideas.com Newswire) Simultaneously, demand is growing for Reliq Health's iUGO Care software as virtual healthcare delivery increases during the COVID-19 pandemic.

Voyager Shares Lift Off After Firm Signs License Deal With Pfizer for Next-Gen AAV Capsids for Gene Therapy Programs
October 7, 2021 (Investorideas.com Newswire) Shares of Voyager Therapeutics Inc. traded 51% higher after the company reported it entered into a license and option agreement with Pfizer Inc. for two of its TRACER AAV capsids

SmileDirectClub Granted Patent for Mobile Oral Care Bus to Serve Remote Regions in the US & UK
October 6, 2021 (Investorideas.com Newswire) SmileDirectClub Inc. shares traded 15% higher after the company reported that the U.S. Patent & Trademark Office has allowed its new patent for the firm's mobile SmileBus concept whereby its SmileShop on wheels is mobilized to expand access to convenient, affordable oral care in remote areas across the U.S. and the U.K.

Xenon Pharma Shares Gain 80% on Positive Data in Phase 2b Focal Epilepsy Trial
October 5, 2021 (Investorideas.com Newswire) Shares of Xenon Pharmaceuticals Inc. soared to a new 52-week high after the company reported topline data from its Phase 2b X-TOLE clinical study demonstrating that its epilepsy drug candidate XEN1101 successfully met several primary and secondary efficacy endpoints

Merck and Ridgeback Post Interim Data From Phase 3 Antiviral Drug Trial Showing 50% Reductions in Hospitalizations and Deaths in Mild and Moderate COV
October 4, 2021 (Investorideas.com Newswire) Shares of Merck & Co. Inc. traded 9% higher after the company reported that in a global Phase 3 clinical trial conducted together with its partner Ridgeback Biotherapeutics

COVID-19 Vaccine Could Be Approved in Q4/21 for 5 to 11 Year Olds
October 1, 2021 (Investorideas.com Newswire) "Label extension for BioNTech and Pfizer's Comirnaty [vaccine] to include use in these younger individuals ought to buoy revenue growth near term," noted an H.C. Wainwright & Co. report.

Alzamend Shares Rise After FDA Gives Positive Response to Pre-IND Filing for Immune-Boosting Alzheimer's Vaccine
October 1, 2021 (Investorideas.com Newswire) Shares of Alzamend Neuro Inc. traded 36% higher after the company reported that the U.S. FDA responded favorably to its Pre-IND application for AL002

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Related Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

Zonetail Inc. Announces Debt Settlement
Toronto, Ontario--(Newsfile Corp. - October 15, 2021) - Zonetail Inc. (TSXV: ZONE) (OTCQB: ZTLLF) ("Zonetail" or the "Company"), is pleased to report the settlement of up to $225,000 of debt through the issuance of common shares of the Company (the "Debt Settlement"). Pursuant to the Debt Settlement, the Company would issue 3,750,000 common shares of the Company (the "Shares") at a deemed price of $0.06 per Share to convertible debenture holders, on account of principal and accrued interest...

Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones
Calgary, Alberta--(Newsfile Corp. - October 15, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that as a result of successful process development of the active pharmaceutical ingredient ("API") of its lead drug MB-204, the Company has now entered an important milestone of engineering and subsequent current good manufacturing practices ("cGMP") run of its multi-kilogram batches of MB-204 in partnership...

PharmaDrug Announces Positive Research Results for Cepharanthine in the Treatment of Multiple Cancers When Used Alone and in Combination with Chemotherapy
Cepharanthine reproducibly demonstrates potential as a monotherapy in treating multiple cancers with unsatisfactory treatment optionsIdentified 4 cancer types where cepharanthine provides additive or synergistic inhibitory effects when combined with standard of care (SoC) chemotherapyContinued focus on esophageal cancer as most highly responsive cancer examinedFDA IND-enabling animal efficacy studies planned for Q4, 2021 examining cepharanthine efficacy alone, and in combination with, SoC chemotherapy to support Phase 1 and 2 clinical studies Toronto, Ontario--(Newsfile Corp. - October...

ScreenPro Security Completed Upgrade of US Listing to OTCQB
Toronto, Ontario--(Newsfile Corp. - October 15, 2021) - ScreenPro Security Inc. (CSE: SCRN) ("ScreenPro" or the "Company") is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). The shares ScreenPro commenced trading on the OTCQB at market open on October 12th under the symbol "SCRSF". Lena Kozovski, CEO of ScreenPro Security commented, "This new listing on the OTCQB provides provides a higher profile for...

Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer
Calgary, Alberta--(Newsfile Corp. - October 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Fraser C. Henderson Sr., MD, as its Chief Medical Officer.Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is Director of The Metropolitan Neurosurgery Group, LLC, Chief of Neurosurgery at...

Subscribe to Biotech News